English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We thank Antonio Sorlózano-Puerto, José María Navarro-Marí, and José GutiérrezFernández for their comment on our paper (1, 2) and greatly appreciate their data on fosfomycin susceptibility in Campylobacter species isolates. To our knowledge, this is the first report on Campylobacter species susceptibility to fosfomycin since 1995 (3). As we stated in the Discussion, data on rates of resistance to fosfomycin in Campylobacter spp. are scarce and “further studies are needed to establish MIC breakpoints and define resistance rates in different geographical areas”; therefore, any information is of great value. Given their findings, we emphasize that determining the MIC of fosfomycin is crucial previous to deciding on its use in the therapy of difficultto-treat Campylobacter species infections.

Reply to “Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin”